Information Provided By: 
Fly News Breaks for October 3, 2019
FOLD
Oct 3, 2019 | 07:26 EDT
Cowen analyst Ritu Baral noted Amicus released full 24-month functional data from its Pompe trial which she said is very encouraging for a successful Phase 3. She strongly believes the data establishes the company's ERT position in the Pompe treatment landscape. The analyst said the current climate presents a buying opportunity for the shares. Baral reiterated her Underperform rating and $31 price target on Amicus shares.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
